Lenvatinib Pill

DRUG4 trials

Conditions

Advanced Solid TumorCancerCarcinoma, HepatocellularClear Cell Renal Cell CarcinomaColorectal AdenocarcinomaColorectal CancerCutaneous Squamous Cell CarcinomaEpithelial Ovarian Cancer

Phase 1

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

CompletedNCT03524326

Memorial Sloan Kettering Cancer CenterCutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma +1

Start: 2018-04-30End: 2022-10-13Updated: 2025-05-13

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruitingNCT05620134

Salubris Biotherapeutics IncAdvanced Solid Tumor, Cancer, Clear Cell Renal Cell Carcinoma +19

Start: 2022-10-17End: 2026-02-20Target: 263Updated: 2024-10-15

Phase 2

Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative

Active, not recruitingNCT05113186

Assistance Publique - Hôpitaux de ParisHepatocellular Carcinoma

Start: 2022-02-02End: 2026-10-02Updated: 2026-01-29

Phase 4

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

NCT04127396

Beijing Ditan HospitalCarcinoma, Hepatocellular, Portal Vein Tumor Thrombus

Start: 2019-09-01End: 2021-12-01Target: 72Updated: 2021-07-23

Related Papers

Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study

Cancer2021-07-08136 citations

A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).